Galectin Therapeutics Inc. - Common Stock (GALT)

Galectin Therapeutics is a biotechnology company focused on developing innovative therapies for serious diseases by targeting galectin proteins, which play a crucial role in the body’s immune response and disease progression

The company is dedicated to advancing its research and product pipeline, particularly in the realms of liver disease and cancer, aiming to improve patient outcomes through novel treatments. By leveraging its expertise in galectin biology, Galectin Therapeutics seeks to create safe and effective solutions that can address unmet medical needs and enhance the quality of life for patients suffering from various conditions.